Toray out-licenses novel Parkinson’s therapy
Toray Industries out-licensed TRK-820 (nalfurafine hydrochloride), renamed IMM02-KORA, to Immunis for exclusive development and commercialization in the US, Canada and Europe, with upfront, milestone and royalty payments to Toray. Immunis has filed an IND with the US Food and Drug Administration to initiate a Phase I trial targeting L‑dopa‑induced dyskinesia, repositioning a known compound to address Parkinson’s treatment-related movement complications.
Why it mattersFDA IND for Phase I was submitted; reassess Immunis's clinical timeline and licensing risk.
Entities Mentioned
Toray Industries, Inc
People Mentioned
Kyle Umipig